Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Omeros Corp (NQ: OMER)
13.72 USD  +0.08 (+0.62%)
Official Closing Price  /  Updated: 4:00 PM EST, Jan 28, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 199,509
Open 13.76
Bid (Size) 13.11 (1)
Ask (Size) 14.25 (30)
Prev. Close 13.64
Today's Range 13.67 - 14.17
52wk Range 12.52 - 20.92
Shares Outstanding 48,292,608
Dividend Yield N/A
Performance
YTD
+0.81%
+0.81%
1 Month
-5.67%
-5.67%
3 Month
-19.97%
-19.97%
6 Month
-10.93%
-10.93%
1 Year
+8.67%
+8.67%
Top News
More News
myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
myTomorrows, a global health technology company, and Omeros Corporation (Nasdaq: OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule... Read More
from Business Wire News Releases
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
Omeros Corporation (Nasdaq: OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 2019 Immuno-Oncology Congress... Read More
from Business Wire News Releases
More News
Read More
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
from Business Wire News Releases
Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva
from Business Wire News Releases
Omeros Announces Pricing of Upsized Public Offering of Common Stock
from Business Wire News Releases
Omeros Announces Proposed Public Offering of Common Stock
from Business Wire News Releases
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
from Business Wire News Releases
How The Parts Add Up: XPH Headed For $54
category ETFs
from ETF Channel
Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online
from Business Wire News Releases
Noteworthy Thursday Option Activity: CLDR, ONCE, OMER
category Stocks
from Market News Video
Here's Why Omeros Stock Is Tumbling Today
category OMER , Market News
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.